Sareum Announces Success Milestones in Collaboration with Schering
News Jun 09, 2006
In this collaboration, first announced in October 2005, Sareum has succeeded in using X-ray crystallography to determine, on schedule, the three-dimensional structure of one of Schering’s drug discovery research targets.
As a result of this achievement, Sareum has received success milestone payments.
Sareum will continue to provide structure information to support Schering’s drug discovery research on this target in return for further success milestone payments.
Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are extremely pleased to have achieved these success milestones in this important collaboration."
"The successful determination of this difficult and previously un-solved protein structure further demonstrates our leading position in structure-based drug discovery research."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE